7. Diabetes Technology: Standards of Care in Diabetes—2025

Diabetes Care, Journal Year: 2024, Volume and Issue: 48(Supplement_1), P. S146 - S166

Published: Dec. 9, 2024

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide components diabetes care, general treatment goals guidelines, tools evaluate quality care. Members ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating Standards annually, or more frequently as warranted. For a detailed description standards, statements, reports, well evidence-grading system full list Committee members, please refer Introduction Methodology. Readers who wish comment on invited do so at professional.diabetes.org/SOC.

Language: Английский

---

15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025

Diabetes Care, Journal Year: 2024, Volume and Issue: 48(Supplement_1), P. S306 - S320

Published: Dec. 9, 2024

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide components diabetes care, general treatment goals guidelines, tools evaluate quality care. Members ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating Standards annually, or more frequently as warranted. For a detailed description standards, statements, reports, well evidence-grading system full list Committee members, please refer Introduction Methodology. Readers who wish comment on invited do so at professional.diabetes.org/SOC.

Language: Английский

---

Automated insulin delivery during the first 6 months postpartum (AiDAPT): a prespecified extension study

The Lancet Diabetes & Endocrinology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Case series of a hybrid closed loop therapy system used in pregnancy

Acta Diabetologica, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 13, 2025

Language: Английский

---

Automated insulin delivery in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis

Acta Diabetologica, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 10, 2025

Abstract Aims To assess the efficacy and safety of automated insulin delivery (AID) systems compared to standard care in managing glycaemic control during pregnancy women with Type 1 Diabetes Mellitus (T1DM). Methods We searched MEDLINE, Cochrane Library, registries conference abstracts up June 2024 for randomized controlled trials (RCTs) observational studies comparing AID pregnant T1DM. conducted random effects meta-analyses % 24-h time range 63–140 mg/dL (TIR), hyperglycaemia (> 140 mg/dl > 180 mg/dL), hypoglycaemia (< 63 < 54 total dose (units/kg/day), glycemic variability (%), changes HbA1c maternal fetal outcomes. Results Thirteen (450 participants) were included. significantly increased TIR (Mean difference, MD 7.01%, 95% CI 3.72–10.30) reduced (MD – 5.09%, 9.41 0.78 2.44%, 4.69 0.20, respectively). Additionally, was 1.66%, 2.73 0.58). Other outcomes did not differ significantly. Conclusion effectively improve T1DM by increasing reducing without any observed adverse short-term on

Language: Английский

---

Mixed Methods RCT comparing quality of life for pregnant women with type 1 diabetes using Hybrid Closed-Loop (HCL) to Sensor-Augmented Pump Therapy (SAPT)

Endocrine Practice, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Efficacy of automated insulin delivery systems in people with type 1 diabetes: a systematic review and network meta-analysis of outpatient randomised controlled trials

EClinicalMedicine, Journal Year: 2025, Volume and Issue: 82, P. 103190 - 103190

Published: April 1, 2025

The comparative efficacy of automated insulin delivery (AID) systems and other treatment options for type 1 diabetes, accounting the certainty evidence (CoE), is unknown. We searched PubMed, EMBASE, Cochrane Central Register Controlled Trials ClinicalTrials.gov included outpatient randomised controlled trials (RCTs) published until January 8, 2025, in people with diabetes a three-week or longer intervention AID (PROSPERO registration number: CRD42023395492). performed pairwise network meta-analyses used Risk Bias tool 2 Grading Recommendations Assessment, Development Evaluation methods to determine CoE each outcome. A total 46 studies involving seven 4113 participants were included, which 29 17 had low moderate risks bias, respectively. systems, including hybrid closed-loop (HCL), advanced HCL (AHCL) full (FCL) evaluated 20, 25 studies, meta-analysis did not indicate global inconsistencies but publication bias all glycaemic outcomes. varied between very high, depending on outcome under consideration. Compared pump therapy, percentage time range 70-180 mg/dl was greater use (HCL: 19.7% [95% confidence interval 13.2%; 26.1%], CoE; AHCL: 24.1% [18.2%; 29.9%], FCL: 25.5% [11.1%; 39.9%], high CoE). above 180 250 lower AHCL, average, by 19.6% (14.0%; 25.1%), CoE, 14.8% (8.8%; 20.8%), uncertain regarding overall effect below 70 54 HbA1c. improve outcomes varying degrees CoE. German Federal Ministry Education Research (BMBF; grant 01KG2203).

Language: Английский

---

Technology advances in diabetes pregnancy: right technology, right person, right time

Diabetologia, Journal Year: 2024, Volume and Issue: 67(10), P. 2103 - 2113

Published: July 5, 2024

This review outlines some of the extraordinary recent advances in diabetes technology, which are transforming management type 1 before, during and after pregnancy. It highlights improvements associated with use continuous glucose monitoring (CGM) but acknowledges that neither CGM nor insulin pump therapy adequate for achieving pregnancy targets. Furthermore, even hybrid closed-loop (HCL) systems clinically effective outside may not confer additional benefits throughout To date, there is only one HCL system, CamAPS FX, a strong evidence base pregnancy, suggesting system specific. stark contrast to where category The FX has rapidly adaptive algorithm lower targets across all maternal categories, meaning it applicable women diabetes, before For reproductive years living 2 relative merits using non-insulin pharmacotherapies vs technology (dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists sodium-glucose cotransporter inhibitors) unknown. Despite urgent unmet need potential benefits, studies pharmacotherapy extremely limited pregnant diabetes.

Language: Английский

---

Automated insulin delivery in pregnant women with type 1 diabetes: a systematic review and meta-analysis

Acta Diabetologica, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 17, 2025

Language: Английский

---

Changes to insulin pump settings throughout pregnancy for individuals using assisted hybrid closed-loop therapy versus sensor-augmented pump therapy

Journal of Diabetes and its Complications, Journal Year: 2025, Volume and Issue: 39(4), P. 109000 - 109000

Published: March 10, 2025

Language: Английский

---